Dual anti-angiogenic chemotherapy with temozolomide and celecoxib in selected patients with malignant glioma not eligible for standard treatment
Aim: Due to their high rate of neo-angiogenesis, malignant gliomas may qualify for treatment with anti-angiogenic substances. We report on a series of patients with malignant glioma not eligible for standard postoperative combined radiochemotherapy due to decreased health status. Patients and Method...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
September 2015
|
| In: |
Anticancer research
Year: 2015, Volume: 35, Issue: 9, Pages: 4955-4960 |
| ISSN: | 1791-7530 |
| DOI: | undefined |
| Online Access: | Verlag, teilw. kostenfrei, Volltext: http://dx.doi.org/undefined Verlag, teilw. kostenfrei, Volltext: http://ar.iiarjournals.org/content/35/9/4955 
|
| Author Notes: | Johannes Kerschbaumer, Franziska Anna Schmidt, Astrid Ellen Grams, Martha Nowosielski, Daniel Pinggera, Konstantin Robert Brawanski, Ondra Petr, Claudius Thomé, Jochen Tuettenberg, Marcel Seiz and Christian Franz Freyschlag |
| Summary: | Aim: Due to their high rate of neo-angiogenesis, malignant gliomas may qualify for treatment with anti-angiogenic substances. We report on a series of patients with malignant glioma not eligible for standard postoperative combined radiochemotherapy due to decreased health status. Patients and Methods: A total of nine patients with malignant glioma, postoperatively presenting with a Karnofsky performance score (KPS) below 70, were treated with standalone metronomic low-dose chemotherapy with temozolomide and celecoxib (cyclo-oxygenase-2 inhibitor). Overall survival was defined as the primary end-point and the functional status (KPS) and time to progression as secondary end-points of our analysis. Results: The median KPS after surgery was 60. Treatment achieved a decrease in tumor and edema volume and, more importantly, preserved the functional status defined as the ability to care for self (KPS 70%) until disease progression. No notable side-effects were recorded. Conclusion: In patients with decreased general condition (KPS <70), not eligible for standard treatment, anti-angiogenic therapy offers a reasonable alternative approach. Our results indicate prolonged survival and preserved quality of life in comparison to best supportive care. |
|---|---|
| Item Description: | Gesehen am 06.03.2018 |
| Physical Description: | Online Resource |
| ISSN: | 1791-7530 |
| DOI: | undefined |